Skip to main content

What is Braftovi used to treat?

Medically reviewed by Judith Stewart, BPharm. Last updated on Dec 30, 2024.

Official Answer by Drugs.com

Braftovi is used in combination with other drugs to treat patients with advanced melanoma, advanced non-small cell lung cancer and advanced colorectal cancer with BRAF gene mutations.

Braftovi is an oral small molecule BRAF kinase inhibitor.

Melanoma

Braftovi (encorafenib) is used in combination with Mektovi (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Roughly 50% of patients diagnosed with metastatic melanoma test positive for the BRAF mutation, and it is the most common genetic mutation in metastatic melanoma.

Braftovi is not indicated for the treatment of patients with wild-type BRAF melanoma.

Colorectal Cancer

Braftovi is used in combination with Erbitux (cetuximab) for the treatment of adult patients with
metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Braftovi is also used in combination with Erbitux (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) for the first-line treatment of patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
- This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

BRAF mutations are estimated to occur in up to 15% of people with metastatic colorectal cancer.

Braftovi is not indicated for treatment of patients with wild-type BRAF CRC.

Non-Small Cell Lung Cancer

Braftovi is used in combination with Mektovi (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

BRAF mutations are estimated to occur in 2% to 5% of people with metastatic non-small cell lung cancer.

Braftovi is not indicated for the treatment of patients with wild-type BRAF NSCLC.

Related questions

References
  • Braftovi (encorafenib) prescribing information. Revised 12/2024. Pfizer Inc. New York, NY. Accessed Dec 29, 2024 at https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf

Read next

How effective Is Keytruda for metastatic melanoma?

Keytruda (pembrolizumab) is an immunotherapy known as a PD-1 inhibitor, approved by the FDA for the treatment of unresectable or metastatic melanoma. This therapy has transformed the outlook for many patients with advanced melanoma, offering the potential for extended survival and durable responses in some cases. At 10 years, 34% of patients treated with Keytruda were still alive, compared to 23.6% for those treated with ipilimumab, another immunotherapy.

Continue reading

How effective are Opdivo and Yervoy when taken together?

Opdivo (nivolumab) and Yervoy (ipilimumab) are two anticancer medications. While they are both effective treatment options for many different types of cancer, research shows they work better when taken together for some types of cancer. The effectiveness of taking Opdivo and Yervoy depends on the individual person and what type of cancer they are treating. Continue reading

Opdivo vs Opdivo Qvantig: What is the Difference?

Opdivo and Opdivo Qvantig are both immunotherapy treatments containing nivolumab that help fight cancer by interfering with cancer cell growth and spread. However, they have several key differences in their administration method, approved uses, and patient eligibility. Continue reading

See also:

Related medical questions

Drug information

Related support groups